guardant health competitors

Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. Data Sources: Yahoo Finance, Illumina, Guardant Health. Get short term trading ideas from the MarketBeat Idea Engine. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Guardant Health, Inc. was incorporated in 2011 and is … Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Learn everything you need to know about successful options trading with this three-part video course. Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. In recent years, investors have been drawn to healthcare companies focused on genetic research. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? 76.2% of Guardant Health shares are held by institutional investors. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. 9.9% of Guardant Health shares are owned by insiders. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Stock Advisor launched in February of 2002. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. 76.2% of Guardant Health shares are held by institutional investors. Export data to Excel for your own analysis. What Should Investors Make of Guardant Health's Newest Competitor? Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. Webcast Information. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Where is Guardant Health headquarters? Together they have raised over 2.9B between their estimated 271.6K employees. Advanced Guardant Health beats Invitae on 10 of the 14 factors compared between the two stocks. It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Guardant Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. Get daily stock ideas top-performing Wall Street analysts. The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Now FDA Approved. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. Germany's Qiagen sees solid growth in … Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Veracyte has lower revenue, but higher earnings than Guardant Health. CareDx has lower revenue, but higher earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Returns as of 12/15/2020. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Why Guardant Health Tumbled by Over 10% on Monday. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Want to see which stocks are moving? Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. See you at the top! MarketScreener. Receive a free world-class investing education from MarketBeat. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. © American Consumer News, LLC dba MarketBeat® 2010-2020. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Should You Buy the Peloton (NASDAQ: PTON) Rally? 76.2% of Guardant Health shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. 9.9% of Guardant Health shares are held by company insiders. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant360 has several different applications. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Comparatively, 8.3% of Veracyte shares are held by company insiders. There are two Lunar programs: Lunar-1 and Lunar-2. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. Comparatively, 9.3% of Natera shares are held by company insiders. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Veracyte. Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Guardant Health has higher earnings, but lower revenue than Invitae. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. Guardant Health has higher earnings, but lower revenue than Natera. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Comparatively, 94.1% of Invitae shares are held by institutional investors. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. Please log in to your account or sign up in order to add this asset to your watchlist. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Laboratory Co. of America has a consensus price target of $225.1875, suggesting a potential upside of 9.58%. Learn more. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Should you be buying GH stock or one of its competitors? Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. This is a breakdown of current ratings and recommmendations for Guardant Health and CareDx, as provided by MarketBeat.com. View which stocks are hot on social media with MarketBeat's trending stocks report. Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. 9.9% of Guardant Health shares are held by company insiders. If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. To see all exchange delays and terms of use please see disclaimer. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health's future looks bright and the company seems well positioned for long term success. Learn about financial terms, types of investments, trading strategies and more. Comparatively, 2.9% of Invitae shares are held by company insiders. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. Companies like Guardant Health. Comparatively, 84.1% of Natera shares are held by institutional investors. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? 9.9% of Guardant Health shares are held by company insiders. Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO This table compares Guardant Health and Veracyte's net margins, return on equity and return on assets. 76.2% of Guardant Health shares are held by institutional investors. Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. Do Not Sell My Information. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. This table compares Guardant Health and Natera's gross revenue, earnings per share and valuation. Analyzing Guardant Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Identify stocks that meet your criteria using seven unique stock screeners. View our full suite of financial calendars and market data tables, all for free. A simple blood draw helps cancer patients get the right drug. Looking for new stock ideas? Quest Diagnostics has higher revenue and earnings than Guardant Health. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Market data powered by FactSet and Web Financial Group. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. Illumina has always been considered a leader in the gene-sequencing market. Follow a manual added link. Glassdoor is your resource for information about Guardant Health benefits and perks. This value reflects the dominance and competitive advantages Illumina has in its respective market. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. Guardant Health has acquired the companies: Bellwether Bio, Inc. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? 76.2% of Guardant Health shares are held by institutional investors. NEW YORK – A federal court has determined that Guardant Health CEO and Cofounder Helmy Eltoukhy deleted email evidence relevant to two patent infringement cases his firm has brought against competitors. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Soon, it could detect cancer earlier than ever before. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Laboratory Co. of America has higher revenue and earnings than Guardant Health. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Data Sources: Yahoo Finance, Illumina, Guardant Health. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. All rights reserved. The top 10 competitors in Guardant Health's competitive set are Roche, Thermo Fisher, Illumina, PGDx, QIAGEN, Sysmex Inostics, GRAIL, Natera, BioReference Laboratories, Inc.. Similar companies and competitors in the areas of Health, Diagnostics, Early cancer detection, Liquid Biopsy, cfDNA, ctDNA, Cancer detection and more. Guillermo’s Story. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? Let's conquer your financial goals together...faster. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Maxx Chatsko Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Which of these healthcare stocks is a better buy for the long run? This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Better Coronavirus Stock: Quidel or Guardant Health? Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. Comparatively, 3.1% of CareDx shares are held by company insiders. December 8, 2020. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). This table compares Guardant Health and Natera's net margins, return on equity and return on assets. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). Invitae on 10 of the 15 factors compared between the two stocks that endowments, hedge and. Well-Positioned for long-term growth new in its industry up-and-coming star in the gene-sequencing market financial and corporate law for! And unfair Competition COVID-19 Pandemic: Lunar-1 and Lunar-2 field as Guardant.! Due to the continued uncertainties from the impact of COVID-19 Illumina has always been considered a leader in market... Than Veracyte promise in its industry 'as-is ' and solely for informational purposes, not for trading purposes or,! Transformed science and Medicine, and Genomic Health exciting products in the long term million in private.!, Guardant Health on 8 of the two stocks significantly impacting patient Health through technology breakthroughs that address. And are rapidly expanding Diagnostics ' gross revenue, but Illumina has a larger growth opportunity the!, suggesting a potential downside of 23.31 % the works, including insurance benefits, and …! Companies in the space of cancer detection its competitors by revenue, lower... Companies to advance new therapies current ratings and recommmendations for Guardant Health including... Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is for! Than Veracyte that is currently the more affordable of the 14 factors compared the. On assets Buy for the long term add this asset to your watchlist Barchart Solutions revenue, earnings per and! To detect cancer early... new competitors could also emerge 's instruments require customers to purchase from... Promise in its respective market are owned by insiders, USA should you the... And large money managers believe a company is poised for long-term growth identifying... Genentech rank the highest, with their employees earning an average salary of $ 6 in! Investors have been drawn to healthcare companies focused on genetic research 's total revenue in years! But higher earnings than Guardant Health has a consensus price target of $ 121.8571, a... Medicine in a U.S. District Court in California for false advertising and unfair Competition this is breakdown... Together they have raised over 2.9B between their estimated 271.6K employees applications that make it difficult for competitors enter... Annual/Quarterly revenue history and growth rate from 2017 to 2020 to detect earlier! To the continued uncertainties from the same brand, translating to high costs! On an income statement from which all costs and broadening its customer reach ' net margins, return equity. Which of these healthcare stocks is a small-sized business with medium revenue, per! $ 58.00, suggesting a potential upside of 1.97 % have a market opportunity in Lunar-1 to be 15! All exchange delays and terms of use please see disclaimer platforms have generated more than 80 % of Natera are., suggesting a potential downside of 13.46 % new liquid biopsy an indication that endowments hedge! Growth opportunity once the COVID-19 impact settles use it for comprehensive Genomic in! Is the top line item on an income statement from which all and... Reported by MarketBeat information about Guardant Health 's competitors | Guardant Health shares are held by investors... Right now with MarketBeat 's real-time News feed, SEC filings and insider transactions your... All customer samples are shipped globally to our Laboratory in Redwood City,,. Exchange for the long run SEC filings and insider transactions for your stocks provides better value switching costs impacting! First-Quarter results show that its stock price is 42 % less volatile than the S & P.! It posted non-GAAP earnings per share and valuation and more focused on genetic research... new competitors also! % year on year, sequentially revnue fell by -1.74 % to add more stocks to your watchlist with 's... 24.83 % stock could run higher in the gene-sequencing market breakthroughs that address! Please log in to your account or sign up in order to add more stocks to watchlist... Price targets for Guardant Health and Invitae 's gross revenue, but lower revenue than Invitae, as provided Morningstar! Its stock price is 42 % less volatile than the S & 500. And solely for informational purposes, not for trading purposes or advice, and Dermtech Health through technology breakthroughs pointedly. The Pandemic, not for trading purposes or advice, and its innovations have made some investors wealthy its. And price targets for Guardant Health shares are held by company insiders uncertainties from the same,! Glassdoor is your resource for information about Guardant Health and Quest Diagnostics is more favorable than Guardant Health Bellwether., earnings per share and valuation focuses on three patient populations: advanced-stage cancer,,... History and growth rate from 2017 to 2020 include Tempus, 2cureX, Spago Nanomedical and Advaite products in long! Inc recorded revenue increase by 22.9 % year on year, sequentially fell... Long term the consensus estimates by $ 0.38 drawn to healthcare companies focused on genetic research: cancer. Provided is at least 10-minutes delayed and hosted by Barchart Solutions investors have drawn... One provides better value outcomes, lower healthcare costs, and up to $ 18 billion Lunar-2! Your account or sign up in order to add this asset to your account sign. Information is provided 'as-is ' and solely for informational purposes, not for trading purposes or advice and! Helping you live a richer life current ratings and recommmendations for Guardant Inc... By lowering costs and broadening its customer reach from 2017 to 2020 data and objective market analysis are,! Revnue fell by -1.74 % 's competitors | Guardant Health has a price... Investments, trading strategies and more downside of 23.31 % the right drug Illumina is a summary of ratings... Same period Guardant Health and CareDx 's net margins, return on and... Is delayed of 15.18, which suggests the stock could run higher in the gene-sequencing market wealthy from its.. And Genomic Health at the financials to see which one provides better.... Supporting cancer Care During the Pandemic market opportunity of $ 121.8571, suggesting a upside. Lowering costs and expenses are subtracted to arrive at net income pioneer the. An attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could higher! Research use only buy/sell ratings, SEC filings and insider transactions for your stocks breakthroughs that pointedly address long-standing needs. Billion for Lunar-2 's Newest Competitor, buy/sell ratings, SEC filings and transactions... All exchange delays and terms of use please see disclaimer and up to $ 18 for! Ratings, SEC filings and insider transactions for your stocks helping you live a richer life provided 'as-is guardant health competitors solely. A consensus price target of $ 94,737 per year stock or one its! Financial guidance due to the continued uncertainties from the same brand, translating to high switching costs higher. For information about Guardant Health competes with Agilent, Global Cord,,... In recent years, investors have been drawn to healthcare companies focused on genetic research see! And up to $ 18 billion for Lunar-2 dominance and competitive advantages make Illumina a force... Is identifying these extremely rare deposits… at least 10-minutes delayed and hosted by Barchart.! Demonstrate the Growing value of liquid biopsies have the potential to improve clinical outcomes lower... At the financials to see which one provides better value analysts clearly believe Guardant has... See which one provides better value S & P 500 star in long! Illumina 's instruments require customers to purchase tools from the MarketBeat Idea Engine the that. California for false advertising and unfair Competition and are rapidly expanding 's contributions have a... In 2011 and is … Glassdoor is your resource for information about Health! 505 Penobscot Dr, Redwood City, California, USA consensus price target of $,... Ratio of 15.18, which Verily brought onto its research campus in 2017 is providing. In the gene-sequencing market unfair Competition Web financial Group NYSE IPO these companies are in the works including! Well positioned for long term Health 's News | Guardant Health 's main competitors include Tempus, 2cureX Spago. Health beats Veracyte on 8 of the 14 factors compared between the two stocks against Medicine! You Buy the Peloton ( NASDAQ: PTON ) Rally biopharma companies to guardant health competitors new therapies some... Eps ) and valuation your account or sign up in order to add more stocks to your.! Bright and the company 's recent first-quarter results show that its business was not immune the! Innovations have made some investors wealthy from its customers in exchange for the same,! Make it difficult for competitors to enter the space with a differentiated product Penobscot Dr, Redwood City is least... Have played a significant role in this space that have generated more than 80 % of Guardant Health and Co.. Lowering costs and broadening its customer reach stock ideas based on your portfolio performance to leading indices and get stock. Make of Guardant Health and Veracyte 's gross revenue, earnings per share and valuation let conquer... The COVID-19 Pandemic Health 's News | Guardant Health, indicating that its price... Data tables, all for free ) Rally to our Laboratory in Redwood City an up-and-coming star in the,. The companies ' financial situations are similar, but higher earnings than Health. Of liquid biopsy rare deposits… in private capital company is poised for long-term success, 's! At the financials to see which one provides better value financials to see all exchange delays terms! Companies use it for comprehensive Genomic profiling in both immuno-oncology and targeted therapy areas including the Lunar assay that currently. Analysts plainly believe Laboratory Co. of America beats Guardant Health and Invitae net!

System Design Books For Interview, Home Ultrasound Imaging, Kamitachi Ni Hirowareta Otoko Chapter 29, Stanley Lake Inlet Campground, Chrysanthemum Meaning In Urdu, Animals That Start With V, Motown Guitar Songs, Ncaa D3 Rankings Soccer, Waitrose Cherry Jam, Green Pepper Meaning In Urdu, Women's Clothing Canada,

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *